ChemoCentryx, Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513437797 Filed on November 12, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $133.3M $124.5M $125.5M
YoY Change 29.8% -0.8% 67.78%
Cash & Equivalents $10.26M $22.32M $13.12M
Short-Term Investments $123.1M $102.2M $112.4M
Other Short-Term Assets $600.0K $600.0K $800.0K
YoY Change 0.0% -25.0% -11.11%
Inventory
Prepaid Expenses
Receivables $400.0K $500.0K $300.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $134.3M $125.6M $126.5M
YoY Change 28.54% -0.69% 65.14%
LONG-TERM ASSETS
Property, Plant & Equipment $1.399M $1.440M $1.200M
YoY Change -1.55% 20.0% -25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.60M $32.70M $2.800M
YoY Change 1.84% 1067.86% -56.25%
Other Assets $160.0K $160.0K $200.0K
YoY Change 0.0% -20.0% -75.0%
Total Long-Term Assets $18.12M $34.33M $4.100M
YoY Change 1.55% 737.34% -53.41%
TOTAL ASSETS
Total Short-Term Assets $134.3M $125.6M $126.5M
Total Long-Term Assets $18.12M $34.33M $4.100M
Total Assets $152.4M $160.0M $130.6M
YoY Change 24.61% 22.48% 52.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $909.0K $692.0K $600.0K
YoY Change 21.2% 15.33% 50.0%
Accrued Expenses $5.649M $5.004M $6.000M
YoY Change -9.86% -16.6% -14.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $314.0K $400.0K $500.0K
YoY Change -37.2% -20.0% 0.0%
Total Short-Term Liabilities $6.872M $6.485M $11.60M
YoY Change -39.19% -44.09% 0.0%
LONG-TERM LIABILITIES
Long-Term Debt $16.00K $100.0K $500.0K
YoY Change -96.0% -80.0% -95.5%
Other Long-Term Liabilities $226.0K $222.0K $500.0K
YoY Change -24.16% -55.6% -91.23%
Total Long-Term Liabilities $242.0K $222.0K $1.000M
YoY Change -18.79% -77.8% -94.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.872M $6.485M $11.60M
Total Long-Term Liabilities $242.0K $222.0K $1.000M
Total Liabilities $7.114M $6.769M $12.60M
YoY Change -40.6% -46.28% -55.63%
SHAREHOLDERS EQUITY
Retained Earnings -$172.9M -$163.3M
YoY Change 28.82%
Common Stock $43.00K $43.00K
YoY Change 19.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.3M $153.2M $118.0M
YoY Change
Total Liabilities & Shareholders Equity $152.4M $160.0M $130.6M
YoY Change 24.61% 22.48% 52.93%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42865408 shares
CY2013Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.00
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13115000
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42865408 shares
CY2013Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
150000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42865408 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.77
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5371204 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2314888 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1450000 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
156281000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22315000
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
102224000
CY2013Q3 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2013Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
523000
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
156281000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
560000
CY2013Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2611479
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13800000
CY2013Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
21326000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1440000
CY2013Q3 ccxi Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments
0
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5004000
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
316467000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
692000
CY2013Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
62000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6485000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
222000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
153184000
CY2013Q3 us-gaap Deferred Revenue
DeferredRevenue
376000
CY2013Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
413000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163319000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
43000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159953000
CY2013Q3 us-gaap Liabilities
Liabilities
6769000
CY2013Q3 us-gaap Long Term Investments
LongTermInvestments
32731000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
125622000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2013Q3 us-gaap Assets
Assets
159953000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40155000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36354547 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36354547 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.38
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5292738 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1567902 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
dei Entity Central Index Key
EntityCentralIndexKey
0001340652
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6267000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244513000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
750000
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
379000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11300000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
298000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
110346000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
3761000
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
522000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134189000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122323000
CY2012Q4 us-gaap Liabilities
Liabilities
11977000
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
16262000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
104480000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2012Q4 us-gaap Assets
Assets
122323000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
117565000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
94234000
CY2012Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
1156000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
117565000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
630000
CY2012Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2012Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7069000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1421000
dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
935650 shares
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Description of Business</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemokine-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company&#x2019;s principal operations are in the United States and it operates in one segment.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Unaudited Interim Financial Information</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December&#xA0;31, 2012 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s financial statements and the notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#xA0;31, 2012 filed with the Securities and Exchange Commission, or SEC, on March&#xA0;14, 2013.</p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M9D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40262000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.09
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26865000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
935650 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M22D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
232636 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
624548 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Reclassifications</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Certain items in the Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current fiscal year&#x2019;s format.</p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.23
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5522876 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Use of Estimates</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div>
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
314000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-633000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29123000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
5335000
us-gaap Investment Income Interest
InvestmentIncomeInterest
360000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
426000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29444000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
119253000
us-gaap Interest Paid
InterestPaid
22000
us-gaap Net Income Loss
NetIncomeLoss
-29130000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5706459 shares
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-365000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
141977000
us-gaap Interest Paid
InterestPaid
39000
us-gaap Net Income Loss
NetIncomeLoss
-30094000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
317000
us-gaap Costs And Expenses
CostsAndExpenses
33003000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-572000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-216000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30012000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3274000
us-gaap Investment Income Interest
InvestmentIncomeInterest
411000
us-gaap Stock Issued1
StockIssued1
10215000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1935000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
82000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
408000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29729000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
445000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2585000
us-gaap Costs And Expenses
CostsAndExpenses
34779000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8655000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66836000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
93582000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3385000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
312000
us-gaap Share Based Compensation
ShareBasedCompensation
4699000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13855000
us-gaap Interest Expense
InterestExpense
46000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64365000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26116000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26124000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1363000
us-gaap Depreciation
Depreciation
426000
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Option Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionForfeited
232636 shares
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
0 shares
ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-1243000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35117000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23439000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7654000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56926000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
81563000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3274000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Share Based Compensation
ShareBasedCompensation
3415000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-27040000
us-gaap Interest Expense
InterestExpense
776000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
38000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60527000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25349000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1337000
us-gaap Depreciation
Depreciation
456000
ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-1960000
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64400000
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36180000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2012Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
121000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10035000
CY2012Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1128000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
141000
CY2012Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
81000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10237000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-10116000
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
11365000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2619000
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1500000
CY2012Q3 us-gaap Interest Expense
InterestExpense
20000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8746000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42839000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
120000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9260000
CY2013Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1522000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
134000
CY2013Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
173000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9553000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-9433000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
11075000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2882000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2013Q3 us-gaap Interest Expense
InterestExpense
14000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8193000

Files In Submission

Name View Source Status
0001193125-13-437797-index-headers.html Edgar Link pending
0001193125-13-437797-index.html Edgar Link pending
0001193125-13-437797.txt Edgar Link pending
0001193125-13-437797-xbrl.zip Edgar Link pending
ccxi-20130930.xml Edgar Link completed
ccxi-20130930.xsd Edgar Link pending
ccxi-20130930_cal.xml Edgar Link unprocessable
ccxi-20130930_def.xml Edgar Link unprocessable
ccxi-20130930_lab.xml Edgar Link unprocessable
ccxi-20130930_pre.xml Edgar Link unprocessable
d592488d10q.htm Edgar Link pending
d592488dex311.htm Edgar Link pending
d592488dex312.htm Edgar Link pending
d592488dex321.htm Edgar Link pending
d592488dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending